Total Funding
31
67
Total FundingSeed raised
Growth Score
-3 pts
Heat Score
-11 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
110975
Trilo Therapeutics is developing best-in-class peptide-drug conjugates that address the dose-limiting toxicity of current generation ADCs.
- Kurt Gish: CEO
- Keith Wilson: Co-Founder and chair SABPast Role: Oxford BioTherapeutics, Chief Scientific Officer
About the Company
Trilo Therapeutics, a San Francisco based company founded by biotech/pharma veterans, is developing best-in-class peptide-drug conjugates (PDC) that will address the dose-limiting toxicity of the current generation of ADCs.
Trilo novel approach uses macrocyclic D-amino acid peptides to replace the antibody component of ADCs. Our conjugates:
- provide superior tumor penetration than ADCs - reduce toxicity compared to traditional L-amino acid peptide-drug conjugates - are compatible with clinically validated payloads and radionuclides - open new treatment modalities based on a "fast in/fast out" mode of action
